Oslo, 2 October 2026: Reference is made to the stock exchange announcement published by Oncoinvent ASA (the “Company”) on 22 September 2026 regarding completion of a private placement and retail offering of in total 1,650,000 new shares at a subscription price of NOK 90 per share (the “Private Placement”), and the mandatory notification of trade and shareholding disclosure published on 23 September 2026 regarding the allocation of new shares to, and temporary share lending by, Linc AB.

In connection with the Private Placement, Linc AB temporarily lent 555,362 existing and unencumbered shares in the Company to ABG Sundal Collier ASA and DNB Carnegie, a part of DNB Bank ASA, acting as managers in the Private Placement (the “Managers”), solely to facilitate delivery-versus-payment (“DVP”) settlement of shares allocated to investors in the Private Placement. Following registration of the share capital increase pertaining to the Private Placement with the Norwegian Register of Business Enterprises, the Managers have now re-delivered the temporarily lent shares to Linc AB, together with the 192,888 new shares allocated to Linc AB in the Private Placement.

Following re-delivery of all temporarily lent shares and the shares allocated in the Private Placement, Linc AB holds 748,250 shares and votes in the Company, equal to 12.21% of the total number of shares and votes in the Company, thereby crossing above the 5% and 10% reporting thresholds pursuant to the NSTA on a consolidated basis, as also described in the announcement made on 23 September 2026.

This information is subject to the disclosure requirements pursuant to section 4-2 of the Norwegian Securities Trading Act.